A Dark Vector Cognition product

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

33K characters. Original on sec.gov ·

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The 6 tables in Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

Financial Review — Results of Operations

Abbott’s revenues are derived primarily from the sale of a broad portfolio of healthcare products under short-term receivable arrangements. Patent protection and licenses, technological and performance features, and inclusion of Abbott’s products under a contract most significantly impact which products are sold; price controls, competition, and rebates most significantly impact the net selling prices of products; and foreign currency translation impacts the measurement of net sales and costs. Abbott’s primary products are medical devices, diagnostic testing products, nutritional products, and branded generic pharmaceuticals.

The following tables detail sales by reportable segment for the three and nine months ended September 30. Percent changes are versus the prior year and are based on unrounded numbers.

Net Sales to External Customers
(in millions)Three Months Ended September 30, 2026Three Months Ended September 30, 2025Total ChangeImpact of Foreign ExchangeTotal Change Excl. Foreign Exchange
Established Pharmaceutical Products$1,614$1,5116.8%(1.6)%8.4%
Nutritional Products2,2622,1535.10.24.9
Diagnostic Products3,3052,25346.70.146.6
Medical Devices5,8265,4486.9(0.5)7.4
Total Reportable Segments13,00711,36514.5(0.3)14.8
Other64n/mn/mn/m
Net Sales$13,013$11,36914.5(0.3)14.8
Total U.S.$5,504$4,29928.0—28.0
Total International$7,509$7,0706.2(0.6)6.8
Net Sales to External Customers
(in millions)Nine Months Ended September 30, 2026Nine Months Ended September 30, 2025Total ChangeImpact of Foreign ExchangeTotal Change Excl. Foreign Exchange
Established Pharmaceutical Products$4,539$4,1549.3%0.6%8.7%
Nutritional Products6,4236,511(1.3)0.8(2.1)
Diagnostic Products8,5776,48032.41.630.8
Medical Devices17,21815,7129.61.87.8
Total Reportable Segments36,75732,85711.91.410.5
Other1312n/mn/mn/m
Net Sales$36,770$32,86911.91.410.5
Total U.S.$14,994$12,74317.7—17.7
Total International$21,776$20,1268.22.35.9

Notes:In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
n/m = Percent change is not meaningful

The 14.8 percent increase in total net sales during the third quarter of 2026, excluding the impact of foreign exchange, was driven by the acquisition of Exact Sciences Corporation (Exact Sciences) and high single-digit growth in Medical Devices and Established Pharmaceutical Products. The Exact Sciences acquisition was completed on March 23, 2026, and its results are reported within the Diagnostic Products segment as Cancer Diagnostics from the date of acquisition. On a reported basis, net sales were unfavorably impacted by foreign exchange as the relatively stronger U.S. dollar decreased total international sales by 0.6 percent and total sales by 0.3 percent.

The 10.5 percent increase in total net sales during the first nine months of 2026, excluding the impact of foreign exchange, reflected higher sales in Diagnostic Products, Medical Devices, and Established Pharmaceutical Products, partially offset by lower sales in Nutritional Products. Sales of Diagnostic Products primarily increased as a result of the acquisition of Exact Sciences, while growth in Medical Devices and Established Pharmaceutical Products reflected higher sales of new and existing products. Abbott’s net sales were favorably impacted by changes in foreign exchange rates as the relatively weaker U.S. dollar increased total international sales by 2.3 percent and total sales by 1.4 percent.

The table below provides detail by sales category for the nine months ended September 30. Percent changes are versus the prior year and are based on unrounded numbers.

(in millions)Nine Months Ended September 30, 2026Nine Months Ended September 30, 2025Total ChangeImpact of Foreign ExchangeTotal Change Excl. Foreign Exchange
Established Pharmaceutical Products —
Key Emerging Markets$3,448$3,12110.5%0.1%10.4%
Other Emerging Markets1,0911,0335.62.03.6
Nutritional Products —
International Pediatric Nutritionals1,4281,3773.71.32.4
U.S. Pediatric Nutritionals1,6131,695(4.8)—(4.8)
International Adult Nutritionals2,3222,334(0.5)1.5(2.0)
U.S. Adult Nutritionals1,0601,105(4.0)—(4.0)
Diagnostic Products —
Core Laboratory4,1283,8995.91.94.0
Rapid and Molecular2,4662,581(4.5)0.9(5.4)
Cancer Diagnostics1,983—n/an/an/a
Medical Devices —
Rhythm Management2,1791,94412.11.510.6
Electrophysiology2,5222,19015.21.413.8
Heart Failure1,1771,0739.70.88.9
Vascular2,3662,2127.01.85.2
Structural Heart1,7671,6924.41.82.6
Neuromodulation7547362.41.11.3
Diabetes Care6,4535,86510.02.37.7

Notes:Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $156 million of sales in the first nine months of 2025 were moved from Structural Heart to Electrophysiology.
Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business.
On March 23, 2026, Abbott completed the acquisition of Exact Sciences. Following the acquisition, the sales of Exact Sciences are presented as Cancer Diagnostics.

In the first nine months of 2026, total Established Pharmaceutical Products sales, excluding the impact of foreign exchange, increased 8.7 percent. Excluding the favorable effect of foreign exchange, sales in Key Emerging Markets for Established Pharmaceutical Products increased 10.4 percent in the first nine months of 2026, led by double-digit growth in several countries across the Latin America and Asia Pacific regions. Other Emerging Markets, excluding the effect of foreign exchange, increased 3.6 percent in the first nine months of 2026.

Excluding the impact of foreign exchange, total Nutritional Products sales in the first nine months of 2026 decreased 2.1 percent, reflecting lower sales volumes across the adult nutritional and U.S. pediatric product portfolios.

In the first nine months of 2026, Diagnostic Products sales increased 30.8 percent, excluding the impact of foreign exchange. The inclusion of Exact Sciences and growth in Core Laboratory were partially offset by a decline in Rapid and Molecular Diagnostics. From the acquisition date of March 23, 2026, Diagnostic Products results included approximately $2.0 billion of sales from Exact Sciences, which are reported as Cancer Diagnostics.

In Core Laboratory, sales increased 4.0 percent in the first nine months of 2026, excluding the impact of foreign exchange, reflecting continued growth of diagnostic test sales on the Alinity® platform across the U.S. and international markets, including Latin America and Europe, partially offset by lower sales in China due to continued challenging market conditions. In Rapid and Molecular Diagnostics, sales decreased 5.4 percent in the first nine months of 2026, excluding the impact of foreign exchange, primarily reflecting lower demand for respiratory virus tests.

Excluding the impact of foreign exchange, total Medical Devices sales increased 7.8 percent in the first nine months of 2026, reflecting double‑digit growth in Electrophysiology and Rhythm Management, as well as high single-digit growth in Heart Failure and Diabetes Care. Diabetes Care sales increased 7.7 percent, excluding the impact of foreign exchange, driven by continued growth in Abbott’s continuous glucose monitoring (CGM) systems in the U.S. and internationally. CGM systems sales totaled $6.2 billion and $5.6 billion in the first nine months of 2026 and 2025, respectively, and increased 8.3 percent, excluding the impact of foreign exchange.

In the first nine months of 2026, Electrophysiology sales increased 13.8 percent, excluding the impact of foreign exchange, primarily reflecting increased sales of ablation catheters and related portfolio products. In Rhythm Management, sales increased 10.6 percent, excluding the impact of foreign exchange, primarily due to growth in Aveir® leadless pacemakers. In Heart Failure, sales increased 8.9 percent, excluding the impact of foreign exchange, primarily reflecting growth across the portfolio of ventricular assist devices and related accessories. In Vascular, sales increased 5.2 percent, excluding the impact of foreign exchange, primarily reflecting growth in endovascular products.

Abbott received several significant product approvals and launched new products in 2026. In May 2026, Abbott announced it secured CE Mark and in August 2026, Abbott announced U.S. Food and Drug Administration (FDA) approval for Libre® Duo, its dual glucose-ketone biowearable sensor. In August 2026, Abbott received CE Mark for its Amulet 360™ Left Atrial Appendage (LAA) Occluder, a device designed to reduce the risk of stroke in patients with atrial fibrillation (AFib). In August 2026, Abbott announced the launch of Similac® 360 Total Care® Made With Whole Milk, in the U.S., a commercially sterile, ready-to-feed liquid infant formula made with whole milk. In September 2026, Abbott announced FDA approval for its TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, which delivers both pulsed field ablation (PFA) and radiofrequency (RF) energy to treat patients with AFib. In September 2026, Abbott launched SimpleScreen™ CRC, an FDA approved blood-based colorectal cancer screening test for adults age 45 and older who are at average risk for the disease.

The gross profit margin percentage was 50.3 percent and 51.7 percent for the third quarter and first nine months of 2026, respectively, compared to 51.7 percent and 52.4 percent for the third quarter and first nine months of 2025. The decrease in the third quarter and the first nine months of 2026 primarily reflects higher intangible amortization expense related to the Exact Sciences acquisition, as well as the unfavorable impact of higher costs and foreign exchange. These factors were partially offset by favorable business mix, including the addition of Exact Sciences, and continued margin improvement initiatives.

Research and development (R&D) expenses increased $154 million to $920 million, or 20.1 percent, in the third quarter of 2026 compared to the prior year, and increased $372 million to $2.6 billion, or 16.9 percent, in the first nine months of 2026 compared to the prior year. The increase in R&D expenses in the third quarter and the first nine months of 2026 primarily reflects the addition of the Exact Sciences business, as well as continued investment in development programs across multiple businesses.

Selling, general, and administrative (SG&A) expenses increased $1.2 billion to $4.3 billion in the third quarter, or 39.8 percent, and increased $2.8 billion to $12.0 billion, or 30.7 percent, in the first nine months of 2026. The increase primarily reflects the addition of the Exact Sciences business and related integration expenses, charges related to recent legal settlements, increased selling and marketing spend to drive growth across various businesses, and the unfavorable impact of foreign exchange.

Business Acquisition

On March 23, 2026, Abbott completed the acquisition of Exact Sciences for approximately $20.6 billion. The acquisition was funded primarily through the issuance of $20.0 billion of long-term debt in March 2026, with the remainder funded with cash on hand. Under the terms of the agreement, Abbott paid $105 per common share in cash. As part of the acquisition, Abbott assumed approximately $2.8 billion of Exact Sciences’ debt, nearly all of which was repaid. The acquisition of Exact Sciences has established Abbott's position in the cancer diagnostics market and expands its portfolio to include products such as Cologuard®, Oncotype DX®, and Cancerguard®.

The preliminary allocation of the fair value of the Exact Sciences acquisition is shown in the table below. During the third quarter of 2026, Abbott recorded measurement period adjustments, including a $3.2 billion increase in acquired intangible assets with a corresponding reduction to goodwill, which resulted in approximately $100 million of additional amortization expense recognized in the third quarter. Allocation of the purchase price of the acquisition will be finalized when the valuation of assets and liabilities is completed. The differences between the preliminary and final allocation could be material.

(in billions)
Acquired intangible assets, non-deductible$16.0
Goodwill, non-deductible8.9
Acquired net tangible assets0.4
Deferred income taxes recorded at acquisition(2.7)
Net debt(2.0)
Total preliminary allocation of fair value$20.6

The goodwill is primarily attributable to future growth opportunities, assembled workforce, potential future technologies, and other intangible assets that do not qualify for separate recognition, as well as expected synergies from combining operations. The acquired net tangible assets consist primarily of property and equipment, trade accounts receivable, trade accounts payable, other current liabilities, and other non-current liabilities.

If the acquisition had occurred as of the beginning of 2025, unaudited pro forma consolidated net sales would have been approximately $12.2 billion and $35.2 billion for the three and nine months ended September 30, 2025, respectively. Unaudited pro forma earnings before taxes for the three months ended September 30, 2025, would have been approximately $1.6 billion, reflecting interest expense of $0.2 billion and amortization expense related to acquired intangible assets of $0.4 billion. Unaudited pro forma earnings before taxes for the nine months ended September 30, 2025, would have been approximately $3.7 billion, reflecting transaction-related expenses of $0.5 billion, interest expense of $0.7 billion, and amortization expense related to acquired intangible assets of $1.1 billion. Unaudited pro forma consolidated net sales would have been approximately $13.0 billion and $37.5 billion for the three and nine months ended September 30, 2026, respectively. Unaudited pro forma earnings before taxes would have been approximately $1.4 billion for the three months ended September 30, 2026. For the nine months ended September 30, 2026, unaudited pro forma earnings before taxes would have been approximately $4.1 billion, after the effect of interest expense of $0.2 billion, amortization expense related to acquired intangible assets of $0.3 billion, and excluding transaction-related expenses of $0.5 billion that were directly attributable to the acquisition. The unaudited pro forma information is not necessarily indicative of the consolidated results of operations that would have been realized had the Exact Sciences acquisition been completed as of the beginning of 2025, nor is it intended to be indicative of future results of operations of the combined entity.

In the first nine months of 2026, Abbott's condensed consolidated results include $2.0 billion of net sales related to Exact Sciences. Earnings of Exact Sciences included in Abbott's condensed consolidated financial statements since the acquisition date are not material to Abbott's consolidated net earnings.

Other (Income) Expense, net

Other (income) expense, net was income of $164 million in the third quarter of 2026, compared to income of $150 million in the third quarter of 2025, and income of $457 million in the first nine months of 2026, compared to income of $414 million in the first nine months of 2025. The higher income in the third quarter of 2026 primarily reflected income associated with the non-service cost components of net pension and post-retirement medical benefit costs. The higher income in the first nine months of 2026 primarily reflected higher income associated with the non-service cost components of net pension and post-retirement medical benefit costs and unfavorable fair value adjustments of contingent consideration liabilities in the prior year that did not reoccur.

Interest Expense, net

Interest expense, net increased by $253 million to $297 million in the third quarter of 2026 and increased by $521 million to $664 million in the first nine months of 2026. In the third quarter and the first nine months of 2026, interest expense increased primarily due to interest on debt incurred related to the acquisition of Exact Sciences.

Taxes on Earnings

Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first nine months of 2026 and 2025, taxes on earnings included $28 million and $91 million, respectively, in excess tax benefits associated with share-based compensation. In the first nine months of 2026 and 2025, taxes on earnings included approximately $540 million and $460 million, respectively, of tax expense related to a deferred tax asset that was recognized as a significant non-cash tax benefit in a prior year. In the first nine months of 2026 and 2025, taxes on earnings also included approximately $95 million of net tax expense and $90 million of net tax benefit, respectively, primarily as the result of the resolution of various tax positions related to prior years.

In September 2023, Abbott received a Statutory Notice of Deficiency (SNOD) from the IRS for the 2019 Federal tax year in the amount of $417 million. The primary adjustments proposed in the SNOD relate to the reallocation of income between Abbott’s U.S. entities and its foreign affiliates. Abbott believes that the income reallocation adjustments proposed in the SNOD are without merit, in part because certain adjustments contradict methods that were agreed to with the IRS in prior audit periods. The SNOD also contains other proposed adjustments that Abbott believes are erroneous and unsupported. Abbott filed a petition with the U.S. Tax Court contesting the SNOD in December 2023.

In June 2024, Abbott received a SNOD from the IRS for the 2017 and 2018 Federal tax years in the amount of $192 million. The matters proposed in the 2017/2018 SNOD are substantially similar to the income allocation adjustments included in the 2019 SNOD. Abbott filed a petition in September 2024 with the U.S. Tax Court contesting the 2017/2018 SNOD in a manner consistent with its petition for the 2019 SNOD.

In October 2024, Abbott received a SNOD from the IRS for the 2020 Federal tax year assessing an additional $443 million of income tax. The primary adjustments proposed in the SNOD are substantially similar to the income allocation adjustments included in the 2017/2018 and 2019 SNODs. Abbott believes that the income reallocation adjustments proposed in the SNOD are without merit. The SNOD also contains other proposed adjustments and omissions that Abbott believes are erroneous and unsupported. In addition to the tax assessment for the 2020 tax year, the 2020 SNOD also contested a deduction for which an estimated $440 million cash tax benefit would be available in a different taxable year as allowed under applicable U.S. tax law. Abbott filed a petition with the U.S. Tax Court contesting the SNOD in December 2024.

Abbott and the IRS are in active discussions regarding several of the disputed items contained in the 2017 – 2020 SNODs.

In July 2024, Abbott received a $413 million tax assessment from the Malaysian tax authorities for the 2023 tax year. The assessment applies a property capital gains tax on the value of the shares associated with the intercompany sale of an affiliate. Abbott believes the assessment of the Malaysian tax authority to be without merit. In October 2025, the Penang High Court upheld the assessment of the Malaysian tax authority. In October 2025, Abbott filed an appeal with the Malaysian Court of Appeals.

There are numerous other income tax jurisdictions for which tax returns are not yet settled, none of which Abbott expects to be individually significant. Abbott intends to vigorously defend its filing positions in all jurisdictions in which it has unresolved tax matters through ongoing discussions with taxing administrations and/or through litigation as necessary. Abbott reserves for uncertain tax positions related to unresolved tax matters where Abbott’s tax filing position does not meet the standard for recognition of an income tax benefit. Abbott continues to believe that the amount of its recorded reserves for uncertain tax positions is appropriate. Reserves for interest and penalties are not significant.

The Organization for Economic Cooperation & Development (OECD) has proposed a two-pillared plan for a revised international tax system. Pillar 1 proposes to reallocate taxing rights among the jurisdictions in which in-scope multinational corporations operate. Pillar 2 proposes to assess a 15 percent minimum tax on the earnings of in-scope multinational corporations on a country-by-country basis. Numerous countries have enacted legislation to adopt the Pillar 2 model rules. On January 5, 2026, the OECD released administrative guidance that, when enacted, exempts U.S.-parented groups from the Pillar 2 minimum tax. Abbott continues to monitor legislative developments and assess any potential impacts on Abbott's operations for both the Pillar 1 and Pillar 2 proposals.

Separation of Abbott's Global Nutrition Business

In October 2026, Abbott announced its intention to separate its Nutrition business into an independent, publicly traded company. The new company's business will include the Nutritional Products segment, which includes a broad portfolio of adult and pediatric nutritional products, including the Similac®, PediaSure®, Pedialyte®, Glucerna®, and Ensure® brands. Abbott intends to separate the business through distribution of shares of the independent Nutrition company to Abbott shareholders. The transaction is intended to qualify as a tax-free separation for U.S. federal income tax purposes. Abbott expects to complete the transaction by the end of 2027, subject to customary conditions, including regulatory approvals, the effectiveness of a registration statement on Form 10, and final approval by the Abbott board of directors.

Liquidity and Capital Resources

The decrease in cash and cash equivalents from $8.5 billion at December 31, 2025, to $4.1 billion at September 30, 2026, primarily reflects the use of cash to fund the cash portion of the acquisition of Exact Sciences and repay the $2.8 billion of debt assumed in the acquisition, and fund payments related to dividends, legal settlements, share repurchases, and capital expenditures in the first nine months of 2026, partially offset by cash generated from operations.

Working capital was $7.3 billion at September 30, 2026, and $9.5 billion at December 31, 2025. The decrease in working capital in 2026 primarily reflects the reduction in cash, partially offset by increases in trade receivables and inventories and a decrease in the current portion of long-term debt.

In the Condensed Consolidated Statement of Cash Flows, Net cash from operating activities for the first nine months of 2026 totaled $5.5 billion, a decrease of approximately $700 million from the prior year. Cash flow from operating activities decreased during the period, primarily due to legal settlement payments, higher inventory levels, and cash payments related to the settlement of equity awards associated with the Exact Sciences acquisition. These factors were partially offset by lower pension contributions and lower cash taxes paid. In the first nine months of 2026, Net cash from operating activities included the payment of cash taxes of $1.3 billion. Net cash from operating activities in the first nine months of 2025 included pension contributions of $256 million and cash tax payments of $1.5 billion.

At September 30, 2026, Abbott’s long-term debt rating was A+ by S&P Global Ratings and Aa3 by Moody’s Investors Service. Abbott expects to maintain an investment grade rating.

As part of the acquisition, Abbott assumed approximately $2.8 billion of Exact Sciences’ debt, nearly all of which has been repaid.

On September 27, 2026, Abbott repaid the €1.14 billion outstanding principal amount on its 1.500% Notes upon maturity. The repayment equated to approximately $1.3 billion. On September 15, 2025, Abbott repaid the $500 million outstanding principal amount of its 3.875% Notes upon maturity. On March 17, 2025, Abbott repaid the $1.0 billion outstanding principal amount of its 2.95% Notes upon maturity.

In the first nine months of 2026, Abbott repurchased approximately 11.6 million of its common shares for $1.0 billion. As of September 30, 2026, $5.6 billion remains available for repurchase under the share repurchase program authorized by the board of directors in October 2024.

In each of the first three quarters of 2026, Abbott declared a quarterly dividend of $0.63 per share on its common shares, which represents an increase of 6.8 percent over the $0.59 per share dividend declared in each of the first three quarters of 2025.

Legislative Issues

Abbott’s primary markets are highly competitive and subject to substantial government regulations throughout the world. Abbott expects debate to continue over the availability, method of delivery, and payment for healthcare products and services. It is not possible to predict the extent to which Abbott or the healthcare industry in general might be adversely affected by these factors in the future. A more complete discussion of these factors is contained in Item 1, Business, and Item 1A, Risk Factors, in our Annual Report on Form 10-K for the year ended December 31, 2025.

Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements

Under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Abbott cautions that any forward-looking statements made by Abbott are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological, and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

PART I. FINANCIAL INFORMATION

Previous: Cover and table of contents · Next: Item 4. Controls and Procedures